Implantable Cardioverter Defibrillators in Cardiovascular Practice: Report of the Policy Conference of the North American Society of Pacing and Electrophysiology

Pacing and Clinical Electrophysiology

Volumn 14, Issue 6, 1991, Pages 969-979

  LEHMANN, MICHAEL H ^a   SAKSENA, SANJEEV ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; ARTIFICIAL HEART PACEMAKER; CARDIOLOGY; HUMAN; NORTH AMERICA;

EID: 0025739939     PISSN: 01478389     EISSN: 15408159     Source Type: Journal    
DOI: 10.1111/j.1540-8159.1991.tb04143.x     Document Type: Article

References (86)

1. Clinical investigation of implantable antitachycardia devices: Report of the Policy Conference of the North American Society of Pacing and Electrophysiol‐ogy
2. Results of device therapy in high risk patients
3. Optimal resources for implantable cardiac pacemakers
4. The minimally appropriate electrophysiologic study for the initial assessment of patients with documented sustained monomorphic ventricular tachycardia
5. Implantation of the automatic implantable cardioverter defibrillator (AICD): Practical aspects
6. Implantation of the automatic defibrillator: The subxiphoid approach
7. Epicardial implantation of the automatic implantable defibrillator by left subcostal thoracotomy
8. Automatic implantable cardioverter‐defibrillator: Patient survival, battery longevity and shock delivery analysis
9. De‐fibrillation threshold testing and other practices related to AICD implantation: Do all roads lead to Rome
10. The implanted defibrillator: Relation of defibrillating lead configuration and clinical variables to defibrillation threshold
11. Effect of lead polarity on defibrillation threshold
12. Evaluation of electrode polarity on defibrillation efficacy
13. Effect of duration of ventricular fibrillation on defibrillation efficacy in humans
14. Defibrillation energy requirements differ between anesthetic agents
15. Effect of procainamide on the de‐fibrillation threshold in man
16. Effects of acute intravenous and chronic oral amiodarone on defibrillation energy requirements
17. Effect of antiarrhythmic drugs on defibrillation threshold: case report of an adverse effect of mexiletine and review of the literature
18. Evaluation of antiarrhythmic drugs on defibrillation energy requirements in dogs: Sodium channel block and action potential prolongation
19. Improved internal defibrillation efficacy with a biphasic waveform
20. A prospective randomized evaluation of biphasic. versus mono‐phasic waveform pulses on defibrillation efficacy in humans
21. Prospective evaluation of initially ineffective defibrillation pulses on subsequent defibrillation success during ventricular fibrillation in survivors of cardiac arrest
22. Treatment of malignant ventricular arrhythmias with endo‐cardial resection and implantation of the automatic cardioverter‐defibrillator
23. Prophylactic automatic implantable cardioverter‐defibrillator patches in patients at high risk for postoperative ventricular tacharrhythmias
24. Effect of epicardial patch electrodes on transthoracic defibrillation
25. Operative (30‐day) mortality following implantation of the automatic implantable cardioverter defib‐rillator
26. Post‐im‐plant/pre‐discharge automatic implantable defib‐rillator testing: Is it mandatory
27. Relation of the intraoperative defibrillation threshold to successful postoperative defibrillation with an automatic implantable cardioverter defibrillator
28. Termination of malignant ventricular arrhythmias with an implanted automatic defibrillator in human beings
29. Measurement of cardioversion/defibrillation thresholds in man by a truncated exponential waveform and an apical patch‐superior vena caval spring electrode configuration
30. Automatic implantable cardioverter defibrillators and survival of patients with left ventricular dysfunction and malignant ventricular arrhythmias
31. Clinical performance of the implantable cardioverter defibrillator: Electrocardiographic documentation of 101 spontaneous discharges.
32. The automatic implantable cardioverter‐defibrillator: Efficacy, complications and survival in patients with malignant ventricular arrhythmias
33. Long‐term outcome with the automatic implantable cardioverter‐defibrillator
34. Time to first shock and clinical outcome in patients receiving an automatic implantable cardioverter‐defibrillator
35. Mortality associated with the AICD
36. Clinical experience in seventy‐seven patients with the automatic implantable cardioverter defibrillator
37. The Bilitch Report: Performance of implantable cardiac rhythm management devices
38. Reduction in sudden death and total mortality by antiarrhythmic therapy evaluated by electrophysiologic drug testing: Criteria of efficacy in patients with sustained ventricular tachyarrhythmia
39. Determinants of survival in patients with malignant ventricular arrhythmia associated with coronary artery disease
40. Long‐term results of amiodarone therapy in patients with recurrent sustained ventricular tachycardia or ventricular fibrillation
41. Out‐of‐hospital cardiac arrest. Use of electrophysiologic testing in the prediction of long‐term outcome
42. Risk stratification and management of patients with recurrent ventricular tachycardia and other malignant ventricular arrhythmias
43. The automatic implantable cardioverter defibrillator and patient survival: A case control study
44. Device activation and clinical outcome of patients with implantable cardioverter/defibrillators for ventricular tachyarrhythmias
45. Preliminary results of a randomized trial, AICD vs drugs
46. The automatic implantable cardioverter‐defibrillator: Efficacy, complications, and device failures
47. Follow‐up of patients with ventricular tachyarrhythmia treated with the automatic implantable cardiov‐erter defibrillator: Programmed electrical stimulation results do not predict clinical outcome
48. Initial clinical experience with second generation implantable defibrillator
49. Delayed infection of the automatic implantable cardioverter‐defibrillator
50. Complications of automatic implantable cardioverter defibrillators: Radiographic, CT, and echocardio‐graphic evaluation
51. Actuarial incidence and pattern of occurrence of shocks following implantation of the automatic implantable cardioverter defibrillator
52. Prospective randomized study of the clinical efficacy and safety of transvenous cardioversion for termination of ventricular tachycardia
53. Absence of significant post‐defibrillation bradyarrhythmias in patients with automatic implantable defibrillators
54. Psychological responses to the implantable defibrillator: Preliminary observations
55. The impact of the automatic implantable cardioverter defibrillator on quality of life
56. Anxiety and anger in patients with ventricular tachyarrhythmias. Responses after automatic internal cardioverter defibrillator implantation.
57. Psy‐chosocial adaptation to the automatic implantable cardioverter defibrillator
58. Reemployment following implantation of the automatic cardioverter defibrillator
59. New medical technologies in a cost containment environment: Implantable antitachyarrhythmia devices
60. An analysis of the cost effectiveness of the implant‐able defibrillator
61. National Health Services and Practice Pattern Survey: First year report on automatic implantable cardioverter defibrillator operating costs
62. Management of recurrent ventricular tachycardia. Economic impact of therapeutic alternatives
63. Comprehensive clinical electrophysiologic studies in the investigation of documented or suspected tachycardia
64. Long‐term survival of patients with malignant ventricular arrhythmia treated with antiarrhythmic drugs
65. A perspective on the role of catheter ablation in the management of tachyarrhythmias
66. Economic evaluation and the rational diffusion and use of health technology
67. The randomized clinical trial
68. Experience with historical control studies in cancer immunotherapy
69. Multicenter automatic defibrillator implantation trial (MADIT): Design and clinical protocol
70. Future studies with the implantable cardioverter defibrillator
71. Prophylactic use of implantable cardioverter defibrillators: Medical, technical, and economic considerations
72. Development of a clinical database for the implant and follow‐up of cardioverter systems
73. Implant‐able defibrillation: Eight years' clinical experience
74. Antiarrhythmic devices: In search of a common parlance.
75. Implantable cardiac pacemakers: Status report and resource guidelines. Pacemaker Study Group (ICHD)
76. Elective countershock in atriai fibrillation with an intra‐cardiac electrode—a preliminary report
77. Intracavitary electrode catheter cardioversion of atriai tachy‐arrhythmias in the dog
78. Initial clinical experience with an implantable tiered therapy de‐fibrillator
79. Efficacy of an‐titachycardia pacing and cardioversion with the pacemaker‐cardioverter‐defibrillator
80. Initial clinical experience with endocardial defibrillation using an implantable cardioverter‐defibrillator with a triple electrode system
81. Internal cardiac defibrillation in man: Pronounced improvement with sequential pulse delivery to two different lead orientations
82. Efficacy and safety of monophasic and biphasic waveform shocks using a braided endocardial defibrillation lead system
83. Atriai sensing to augment ventricular tachycardia detection by the automatic implantable cardioverter‐defibrillator: A utility study
84. Value of ventricular electrogram recordings in the diagnosis of arrhythmias precipitating electrical device shock therapy
85. Implantable cardioverter/defibrillator—the potential hazard of programmability